邮箱:info@efebio.com
021-65675885
Custom Compound Library (zk012)
A custom library of 113 anti-cancer compounds, primarily covering kinase inhibitors as well as approved and clinical-stage drugs. Suitable for positive-control tests and cross-cancer correlation studies, this collection comprises agents with confirmed or potential anti-tumor activity, with a particular focus on kinase-targeting agents. Numerous cancer types are driven by aberrant activation of specific kinases, molecules target abnormally activated kinases that control cell proliferation, apoptosis and angiogenesis, showing promising performance in pre-clinical and early-clinical research.